UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial

Annals of the rheumatic diseases, 2007-02, Vol.66 (2), p.163-168

2007

Volltextzugriff (PDF)

Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group

Annals of the rheumatic diseases, 2009-06, Vol.68 (6), p.930-937

2009

Volltextzugriff (PDF)

Burden of Infusion-Related Costs and Staff Time for Rheumatoid Arthritis in the Hospital Setting

Value in health, 2013-11, Vol.16 (7), p.A559-A559

2013

Volltextzugriff (PDF)

Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspective

Rheumatology (Oxford, England), 2008-02, Vol.47 (2), p.188-193

2008

Volltextzugriff (PDF)

AB0266 Responsiveness and minimal important difference of the rheumatoid arthritis-work instability scale (ra-wis)

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A867-A867

2013

Volltextzugriff (PDF)

SAT0469 Factors associated with work status and missed work days in rheumatoid arthritis

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.631-631

2013

Volltextzugriff (PDF)

FRI0278 Increased risk of acute and chronic renal comorbidity in ankylosing spondylitis: Results from a population-based study

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.408-408

2013

Volltextzugriff (PDF)

PMS5 Benefit-Risk Analysis of Adalimumab and Alternative Treatments for Moderate-to-Severe Rheumatoid Arthritis

Value in health, 2012-11, Vol.15 (7), p.A439-A440

2012

Volltextzugriff (PDF)

SAT0567 Prevalence Estimates of Axial Spondyloarthritis among Patients in German Rheumatology Practices

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A774-A775

2013

Volltextzugriff (PDF)

AB0450 Effect of adalimumab discontinuation on patient-reported outcomes and work productivity in early rheumatoid arthritis patients who achieved low disease activity following 26 weeks of treatment: Data from the optima study

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.663-663

2013

Volltextzugriff (PDF)

FRI0156 Adalimumab treatment is associated with decreased concomitant RA medication use over 24 months

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.364-364

2013

Volltextzugriff (PDF)

Indirect Comparison of Joint Damage Prevention with Adalimumab V. Abatacept, Each in Combination with Methotrexate, in Early Rheumatoid Arthritis

Value in health, 2013-11, Vol.16 (7), p.A555-A555

2013

Volltextzugriff (PDF)

Cost-Per-Responder Analysis of Biological Agents for the Treatment of Active Ankylosing Spondylitis in Germany

Value in health, 2013-11, Vol.16 (7), p.A562-A562

2013

Volltextzugriff (PDF)

OP0105 Effect of Adalimumab on Physical Function, Health-Related Quality of Life, and Work Productivity in Patients with Peripheral Spondyloarthritis: Results from the Ability-2 Clinical Trial

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A86-A86

2013

Volltextzugriff (PDF)

PMS37 Economic Evaluation Model of Biologic Therapies for Moderate to Severe Psoriatic Arthritis in Germany

Value in health, 2012-11, Vol.15 (7), p.A446-A446

2012

Volltextzugriff (PDF)

PMS70 A COMPARISON OF NON-RESPONDER IMPUTATION AND LAST-OBSERVATION-CARRIED-FORWARD ANALYSIS METHODS IN RHEUMATOID ARTHRITIS CLINICAL TRIALS

Value in health, 2011, Vol.14 (3), p.A136-A136

2011

Volltextzugriff (PDF)

Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis

Clinical and experimental rheumatology, 2011-07, Vol.29 (4), p.624

2011

Volltextzugriff (PDF)

PMS31 Economic Evaluation of Adalimumab Versus Other Biologic Treatments for Moderate to Severe Psoriatic Arthritis in Italy

Value in health, 2012-11, Vol.15 (7), p.A444-A445

2012

Volltextzugriff (PDF)

PMS29 Cost Effectiveness of Adalimumab Versus Golimumab and Placebo in Ankylosing Spondylitis in Italy

Value in health, 2012-11, Vol.15 (7), p.A444-A444

2012

Volltextzugriff (PDF)

PMS46 Economic Evaluation of Adalimumab for the Treatment of Early-and Late-Stage Rheumatoid Arthritis in Italy

Value in health, 2012-11, Vol.15 (7), p.A447-A447

2012

Volltextzugriff (PDF)

Demonstration of compatibility of multiple arterial blood gas syringes with current multi-parameter analyzers

Current medical research and opinion, 2014-07, Vol.30 (7), p.1375-1382

2014

Volltextzugriff (PDF)

PMS37 INDIRECT COMPARISON OF ADALIMUMAB VERSUS ETANERCEPT FOR THE TREATMENT OF PSORIATIC ARTHRITIS

Value in health, 2011, Vol.14 (3), p.A129-A130

2011

Volltextzugriff (PDF)

PMS13 Economic Model of Workplace Impacts of anti-Tnf therapy for Rheumatoid Arthritis in Brazil

Value in health, 2011, Vol.14 (7), p.A563-A564

2011

Volltextzugriff (PDF)

Development of a COPD severity score

Current medical research and opinion, 2006-09, Vol.22 (9), p.1679-1687, Article 1679

2006

Volltextzugriff (PDF)

Is Azithromycin the First-Choice Macrolide for Treatment of Community-Acquired Pneumonia?

Clinical infectious diseases, 2004-07, Vol.39 (1), p.144-145

2004

Volltextzugriff (PDF)

1 – 25 von 127

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(109)
Mit Volltextzugriff
(105)

Publikationsform

Sprache

Englisch
(114)
Italienisch
(13)

Erscheinungsjahr

n.n

Thema

Humans
(46)
Science & Technology
(39)
Life Sciences & Biomedicine
(38)
Male
(28)
Female
(27)
Adult
(22)
Internal Medicine
(21)
Middle Aged
(19)
Aged
(15)
Medicin Och Hälsovetenskap
(15)
Biological And Medical Sciences
(14)
Medical Sciences
(13)
Rheumatology
(11)
Rheumatoid Arthritis
(9)
Antirheumatic Agents - Therapeutic Use
(8)
Diseases Of The Osteoarticular System
(8)
Inflammatory Joint Diseases
(8)
Pharmacology. Drug Treatments
(8)
Treatment Outcome
(8)
Adalimumab
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial

Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group

Burden of Infusion-Related Costs and Staff Time for Rheumatoid Arthritis in the Hospital Setting

Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspective

AB0266 Responsiveness and minimal important difference of the rheumatoid arthritis-work instability scale (ra-wis)

SAT0469 Factors associated with work status and missed work days in rheumatoid arthritis

FRI0278 Increased risk of acute and chronic renal comorbidity in ankylosing spondylitis: Results from a population-based study

PMS5 Benefit-Risk Analysis of Adalimumab and Alternative Treatments for Moderate-to-Severe Rheumatoid Arthritis

SAT0567 Prevalence Estimates of Axial Spondyloarthritis among Patients in German Rheumatology Practices

AB0450 Effect of adalimumab discontinuation on patient-reported outcomes and work productivity in early rheumatoid arthritis patients who achieved low disease activity following 26 weeks of treatment: Data from the optima study

FRI0156 Adalimumab treatment is associated with decreased concomitant RA medication use over 24 months

Indirect Comparison of Joint Damage Prevention with Adalimumab V. Abatacept, Each in Combination with Methotrexate, in Early Rheumatoid Arthritis

Cost-Per-Responder Analysis of Biological Agents for the Treatment of Active Ankylosing Spondylitis in Germany

OP0105 Effect of Adalimumab on Physical Function, Health-Related Quality of Life, and Work Productivity in Patients with Peripheral Spondyloarthritis: Results from the Ability-2 Clinical Trial

PMS37 Economic Evaluation Model of Biologic Therapies for Moderate to Severe Psoriatic Arthritis in Germany

PMS70 A COMPARISON OF NON-RESPONDER IMPUTATION AND LAST-OBSERVATION-CARRIED-FORWARD ANALYSIS METHODS IN RHEUMATOID ARTHRITIS CLINICAL TRIALS

Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis

PMS31 Economic Evaluation of Adalimumab Versus Other Biologic Treatments for Moderate to Severe Psoriatic Arthritis in Italy

PMS29 Cost Effectiveness of Adalimumab Versus Golimumab and Placebo in Ankylosing Spondylitis in Italy

PMS46 Economic Evaluation of Adalimumab for the Treatment of Early-and Late-Stage Rheumatoid Arthritis in Italy

Demonstration of compatibility of multiple arterial blood gas syringes with current multi-parameter analyzers

PMS37 INDIRECT COMPARISON OF ADALIMUMAB VERSUS ETANERCEPT FOR THE TREATMENT OF PSORIATIC ARTHRITIS

PMS13 Economic Model of Workplace Impacts of anti-Tnf therapy for Rheumatoid Arthritis in Brazil

Development of a COPD severity score

Is Azithromycin the First-Choice Macrolide for Treatment of Community-Acquired Pneumonia?

Suchergebnisse filtern